Real World Data Survival Outcomes of First Line Immunotherapy with Pembrolizumab in High Expressers with stage IV Non-Small Cell Lung Cancer. (2026). Radiology and Oncology, 60(3), 450-458. https://www.radioloncol.com/index.php/ro/article/view/4876